Overview

• Ophthalmic device firm's Q4 revenue fell 19% yr/y on lower LDD sales

• Q4 gross profit margin improved, driven by favorable product mix

• Company reported deeper Q4 net loss

Outlook

• RxSight projects 2026 revenue between $120.0 mln and $135.0 mln

• Company expects 2026 gross margin of 70% to 72%

• RxSight forecasts 2026 operating expenses of $150.0 mln to $160.0 mln

Result Drivers

• LAL SALES GROWTH - LAL unit sales increased 12% to 109,615, contributing to revenue despite overall decline

• PRODUCT MIX SHIFT - Gross profit margin improved to 76.6% from 70.7% due to higher percentage of revenue from LAL sales

• LDD SALES DECLINE - LDD revenue decreased 72% in Q4, contributing to overall revenue decline

Company press release: ID:nGNX3B3JHD

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 8 "hold" and 2 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Rxsight Inc is $10.00, about 11.9% above its February 24 closing price of $8.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)